Ellagic acid inhibits HIV‐1 infection in vitro: Potential role as a novel microbicide.

Autor:	Promsong, A., Chuenchitra, T., Saipin, K., Tewtrakul, S., Panichayupakaranant, P., Satthakarn, S., Nittayananta, W.
Předmět:	ANTI-infective agents BENZOPYRANS HIV HIV infections PROTEASE inhibitors HIV integrase inhibitors IN vitro studies
Zdroj:	Oral Diseases; Mar2018, Vol. 24 Issue 1/2, p249-252, 4p, 3 Graphs
Abstrakt:	Objective: To investigate the in vitro effects of ellagic acid on HIV‐1 replication. Methods: Anti‐HIV‐1 activity of ellagic acid was determined in vitro using X4‐tropic HIV‐1NPO3 and R5‐tropic pBaL Env‐recombinant virus. Anti‐HIV‐1NPO3 activity of ellagic acid was investigated at a multiplicity of infection (MOI) of 0.01. Anti‐HIV‐1 integrase and protease activities of ellagic acid were tested using in vitro integration and proteolytic cleavage assays. Results: Ellagic acid, added either before or after HIV‐1NPO3 exposure, suppressed replication of the virus in C8166 cells up to 34%. Ellagic acid showed an anti‐integrase IC50 of 8.7 μM. No cytotoxicity of ellagic acid at concentrations ranging from 12.5 to 100 μM was observed. Conclusion: We conclude that ellagic acid can inhibit HIV‐1 infection without cytotoxicity. Thus, it may be a new effective agent that has potential to be developed as a novel microbicide against HIV‐1. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text